Publications by authors named "Andrea Harkin"

Claim this Profile
T
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.
Alessandro Pastorino, Heshan Liu, Levi Pederson, Valentino Martelli, Timothy Iveson, Andrea Harkin

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.
Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, Luciana Gneo, Tijana Tomasevic, Andrea Harkin

Cell Rep Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.
Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, Rachel S Kerr, Mark P Saunders, Andrea Harkin

JAMA Surg· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Claire Gallois, Qian Shi, Levi D Pederson, Thierry André, Timothy J Iveson, Andrea Harkin

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
Enric Domingo, Caroline Kelly, Jennifer Hay, Owen Sansom, Noori Maka, Andrea Harkin

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Kathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, Guang-Yu Lian, Sara S F Al-Badran, Andrea Harkin

J Exp Clin Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Anja L Frei, Anthony McGuigan, Ritik R A K Sinha, Faiz Jabbar, Luciana Gneo, Andrea Harkin

Lancet Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.
Anja L Frei, Anthony McGuigan, Ritik Rak Sinha, Mark A Glaire, Faiz Jabbar, Andrea Harkin

J Pathol Clin Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Mark P Saunders, Rohan Iype, Caroline Kelly, Jana Crosby, Rachel Kerr, Andrea Harkin

Clin Colorectal Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
Elisa Fontana, Jeff Meyers, Alberto Sobrero, Timothy Iveson, Anthony F Shields, Andrea Harkin

J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis.
Catherine R Hanna, Jose A Robles-Zurita, Andrew Briggs, Andrea Harkin, Caroline Kelly

Clin Colorectal Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
Peter G Alexander, Antonia K Roseweir, Kathryn A F Pennel, Hester C van Wyk, Arfon G M T Powell, Andrea Harkin

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Andrea Harkin

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, Andrea Harkin

JNCI Cancer Spectr· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Andrea Harkin

Lancet Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, Arfon Gmt Powell, Susan Aherne, Andrea Harkin

J Pathol Clin Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, Adrian Cook, Nozomu Yanaihara, Andrea Harkin

JAMA Netw Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrea Harkin

Health Technol Assess· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Victoria Gray, Sarah Briggs, Claire Palles, Emma Jaeger, Timothy Iveson, Andrea Harkin

J Natl Cancer Inst· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Philip J Law, Maria Timofeeva, Ceres Fernandez-Rozadilla, Peter Broderick, James Studd, Andrea Harkin

Nat Commun· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, Timothy Iveson, Rachel S Kerr, Andrea Harkin

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, Jim Cassidy, Niels Henrik Hollander, Andrea Harkin

Lancet Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis